NCT02988882View on ClinicalTrials.gov

OTX-15-002: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Chronic Allergic Conjunctivitis

PHASE3CompletedINTERVENTIONAL
Enrollment

86

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

April 27, 2016

Study Completion Date

April 27, 2016

Conditions
Chronic Allergic Conjunctivitis
Interventions
DRUG

Dexamethasone

OTHER

Placebo Vehicle

Sponsors
All Listed Sponsors
collaborator

ORA, Inc.

INDUSTRY

lead

Ocular Therapeutix, Inc.

INDUSTRY

NCT02988882 - OTX-15-002: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Chronic Allergic Conjunctivitis | Biotech Hunter | Biotech Hunter